An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.The partnership with ViiV Healthcare, GSK’s AIDS drug joint venture with Pfizer (NYSE:PFE), will study the drug Selzentry in a phase 3 study comparing it to another [...]

GlaxoSmithKline (NYSE:GSK) released fourth-quarter 2011 and full-year financial results Tuesday, which happens to be Charles Dickens’ birthday. Somehow I think it’s fitting that Britain’s largest pharmaceutical company discussed its finances on the same day that one of its greatest writers was born. GSK’s results and outlook mark a strong contrast to Britain’s second-largest pharma company, [...]

GlaxoSmithKline (NYSE:GSK) is settling more than 20,000 Avandia cases in a deal reached in court-ordered mediation.Bloomberg News reports that the British pharmaceutical giant reached the deal last month as part of the company’s efforts to resolve legal issues over the last decade surrounding the former blockbuster type 2 diabetes drug.

Generic competition for GlaxoSmithKline (NYSE:GSK) AIDS drug Epzicom is on its way around the world, if not the United States. Yet.The U.S. Food and Drug Administration has given tentative approval for a formulation of the drug made by Cipla, a pharmaceutical company based in Mumbai, India. The tentative approval comes under expedited review from the [...]

Neglected tropicals diseases affect more than one billion people globally, but they have not figured prominently in pharmaceutical industry plans.Those priorities look to be changing with today’s announcement that 13 pharma companies, including GlaxoSmithKline (NYSE:GSK), are joining with public sector and nonprofit partners to control or eliminate neglected tropical diseases (NTDs). The partnership includes the [...]

GlaxoSmithKline (NYSE:GSK) is not giving up finding a role for enlarged prostate drug Avodart as a prostate cancer treatment.A study published today in The Lancet suggests that Avodart, also called dutasteride, could slow prostate cancer’s progression in men who have low-risk prostate cancer under active surveillance. But an editorial also published today in The Lancet [...]

The combination of GlaxoSmithKline (NYSE:GSK) breast cancer drug Tykerb with a drug from rival Roche (OTC:RHHBY) works better compared to using either drug as a standalone therapy, according to a new study.The findings could boost the treatment options for patients and the marketing potential for Tykerb, which falls well short of the Roche drug Herceptin [...]

GlaxoSmithKline (NYSE:GSK) is adding to its cancer drug discovery capabilities by picking up the epigenetics research program from drug partner Astex Pharmaceuticals (NASDAQ:ASTX).Oncology drug discovery and development company Astex will end its work on the the “Climb” collaboration and transfer the research work and assets to British pharma giant GSK, which has its U.S. headquarters [...]

GlaxoSmithKline (NYSE:GSK) isn’t the only big drug company overhauling how pharmaceutical sales representatives talk to doctors. Others are now adapting with new sales practices.GlaxoSmithKline last year made waves when it implemented a new sales model that rewarded sales representatives for their knowledge of GSK drugs and their ability to communicate that knowledge to physicians. The [...]

GlaxoSmithKline (NYSE:GSK) CFO Simon Dingemans is among those at the JP Morgan Global Healthcare Conference this week in San Francisco and he took some time out to discuss respiratory drug candidate Relovair, which the company said would be submitted this year to U.S. and European regulators for approval.Bloomberg Television in this video interview asked Dingemans [...]